80.5 Percent of Teens Experience at Least One Adverse Childhood Experience
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 28, 2024 -- Adverse childhood experiences (ACEs) are very common among adolescents, with 80.5 percent experiencing at least one ACE, according to a study published online Oct. 28 in Pediatrics.
Using data from 16 states, Elizabeth A. Swedo, M.D., M.P.H., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues estimated the prevalence of eight individual and cumulative ACEs among a large population-based sample of adolescents overall and by demographic characteristics.
The researchers found that emotional abuse, household poor mental health, and physical abuse had the highest prevalence (65.8, 36.1, and 32.5 percent, respectively). Overall, 80.5 and 22.4 percent of adolescents experienced at least one ACE and four or more ACEs, respectively. Adolescents who were female (27.7 percent), non-Hispanic multiracial (33.7 percent), non-Hispanic American Indian or Alaska Native (27.1 percent), gay or lesbian (36.5 percent), or bisexual (42.1 percent) or who described their sexual identity some other way or were not sure of their sexual identity (questioning; 36.5 percent) had the highest prevalence of experiencing four or more ACEs.
"Differences in the experiences of ACEs by students belonging to racial, ethnic, or sexual minority groups highlight the need to tailor prevention and mitigation efforts to different social and cultural contexts, rather than employing a universal approach to prevention and intervention, to better support groups disproportionately impacted by ACEs," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-29 06:00
Read more
- Certain Oral Bacteria Tied to Risk for New Head, Neck Squamous Cell Cancer
- First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
- Maternal Short Sleep Duration Linked to Neurodevelopmental Delay in Boys
- Hospital Drug Tests Far More Likely for Minority Teens
- Boarding Admitted Stroke Patients in Emergency Department Financially Costly
- Onions in McDonalds' Quarter Pounders Linked to E. Coli Outbreak Have Been Recalled
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions